PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death.The PARP family consists of 17 individuals. They are all very different in terms of their cell structures and functions. There is confirmed PARP activity in the following proteins: PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2). Additional genes include PARP3, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. The nucleus of the cell contains PARP. The primary responsibility is to identify and alert the enzymatic machinery responsible for SSB repair to single-strand DNA breaks (SSB).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V79155 | DiPT-4 | DiPT-4 is a TOP1/PARP1 dual (bifunctional) inhibitor that can induce a large number of DNA double-strand breaks (DSB), cell cycle arrest and apoptosis in cancer cells. | |
|
V51286 | DR-2313 | 284028-90-6 | DR2313 is a novel and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. |
|
V51301 | EB-47 dihydrochloride | 1190332-25-2 | EB-47 dihydrochloride, a novel inhibitor of PARP-1/ARTD-1 with an IC50 value of 45 nM, shows modest potency against ARTD5 with an IC50 value of 410 nM. |
|
V79448 | Fluorescein-NAD+ | Fluorescein-NAD+ is an alternative radiolabeled NAD and is a substrate for ADP ribosomalization. | |
|
V0307 | G007-LK | 1380672-07-0 | G007-LK is a novel, potent and specific tankyrase (TNKS) 1/2 inhibitor with potential anticancer activity. |
|
V53252 | G244-LM | 1563007-08-8 | G244-LM is a potent and specific tankyrase 1/2 inhibitor that can suppress Wnt signaling. |
|
V21541 | GeA-69 | 2143475-98-1 | GeA-69 (GeA69) is a novel, potent and selective allosteric inhibitor of poly-adenosine-diphosphate-ribose polymerase 14 (PARP14) targeting macrodomain 2, with a Kd of 2.1 µM. |
|
V75781 | HYDAMTIQ | 1201832-32-7 | HYDAMTIQ is a PARP-1/2 inhibitor (IC50= 29-38 nM) with anti-cancer, anti-inflammatory and ischemic protective effects. |
|
V0303 | Iniparib (SAR240550; BSI201; NSC746045; IND71677) | 160003-66-7 | Iniparib (SAR-240550; BSI-201; NSC-746045; IND-71677) is a novel, potent, and irreversible inhibitor of PARP1 [poly(ADP-ribose) polymerase-1] with potential anticancer activity. |
|
V2848 | JW 55 | 664993-53-7 | JW 55 is a potent and selective small molecule inhibitor of β-catenin signaling pathway, it functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2) which are regulators of the β-catenin destruction complex. |
|
V56029 | Lerzeparib | 2459693-01-5 | Lerzeparib is an (ADP-ribose) polymerase (PARP) inhibitor (antagonist) with anti-tumor activity. |
|
V0312 | ME0328 (ME-0328) | 1445251-22-8 | ME0328 (ME-0328) is a novel, potent and selective inhibitor of Poly (ADP-ribose) polymerase (PARP) with potential anticancer activity. |
|
V25740 | MN-64 | 92831-11-3 | MN-64 is a potent and selective inhibitor of Tankyrase 1 and 2 (IC50 = 6 and 72 nM, respectively). |
|
V51306 | MSC-2504877 (M-2912) | 1460286-21-8 | MSC2504877 (M2912) is a potent and oral tankyrase inhibitor, with IC50 values for TNKS, TNKS2, and PARP1 of 0.0007, 0.0008, and 0.54 µM, respectively. |
|
V51310 | N-Descyclopropanecarbaldehyde Olaparib | 763111-47-3 | N-Descyclopropanecarbaldehyde Olaparib is a DOTA-containing analogue of Olaparib N-Descyclopropanecarbaldehyde Olaparib is a ligand based on CRBN that is used to synthesize novel dual PARP PROTAC, DP-C-4, and EGFR. |
|
V2570 | Niraparib (MK-4827) | 1038915-60-4 | Niraparib (formerly known as MK4827; MK-4827; Zejula) is a potent, orally bioavailable and selective inhibitor of PARP1/2 with anticancer activity. |
|
V3788 | Niraparib HCl (MK-4827) | 1038915-64-8 | Niraparib HCl (MK-4827; MK4827; Zejula), the hydrochloride salt of Niraparib, is a PARP1/2 inhibitor that has been approved by for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. |
|
V3790 | Niraparib R-enantiomer | 1038915-58-0 | Niraparib R-enantiomer, the R-isomer of Niraparib, is a potent PARP1 [poly(ADP-Ribose) polymerase] inhibitor (IC50 = 2.4 nM) with anticancer activity. |
|
V3043 | Niraparib Tosylate (MK-4827) | 1038915-73-9 | Niraparib Tosylate (also known as MK-4827; MK4827; Zejula), the tosylate salt of niraparib, is an orally bioavailable and selective inhibitor of PARP1/2 (IC50 = 3.8 nM and 2.1nM) that gained FDA approval in March 2017 for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. |
|
V40825 | Niraparib tosylate hydrate (MK4827) | 1613220-15-7 | Niraparib tosylate hydrate (also known as MK-4827; MK4827; Zejula), the tosylate salt and hydrated form of niraparib, is a selective inhibitor of PARP1/2 (IC50 = 3.8 nM and 2.1nM) that was approved by FDA for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
